HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

COVAC-2 Intelligence Report

Intelligence report

Intelligence Report · ~10 min read

COVAC-2 Intelligence Report

Symvivo · Infectious Disease · COVID-19 · Phase I

Type

Asset Intelligence Report

Generated

Jul 23, 2026

Confidence

Low Confidence · 53%

Evidence

26 items

Sources

20

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

The COVAC-2 vaccine's favorable safety and immunogenicity profile positions it as a competitive option for COVID-19 booster vaccinations, particularly in resource-limited settings. This development necessitates strategic evaluation by pharma companies regarding their existing vaccine portfolios and market positioning. Regulatory context from FDA (New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)) supports the near-term read. Assessment grounded in 18 ranked evidence items (3 high-relevance).

Key Developments

Material intelligence events ranked by strategic relevance.

  1. insightJun 25, 2026

    COVAC-2 Vaccine Emerges as Competitive Booster Option in Resource-Limited Settings

    Intelligence brief refreshed — The COVAC-2 vaccine's favorable safety and immunogenicity profile positions it as a competitive option for COVID-19 booster vaccinations, particularly in resource-limited settings. This development necessitates strategic evaluation by pharma companies regarding their existing vaccine portfolios and market positioning. Regulatory context from FDA (New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)) supports the near-term read. Assessment grounded in 18 ranked evidence items (3 high-relevance).

    View detail
  2. watchJun 25, 2026

    COVAC-2 Vaccine Emerges as Competitive Booster Option in Resource-Limited Settings

    Monitor further trial phases and regulatory approvals for COVAC-2.

    View detail
  3. watchJun 25, 2026

    COVAC-2 Vaccine Emerges as Competitive Booster Option in Resource-Limited Settings

    Watch for uptake trends in low- and middle-income countries as COVAC-2 becomes available.

    View detail
  4. watchJun 25, 2026

    COVAC-2 Vaccine Emerges as Competitive Booster Option in Resource-Limited Settings

    Additional medium- or high-relevance evidence could materially upgrade the assessment of COVAC-2's market potential.

    View detail
  5. regulatoryJun 15, 2026

    Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death

    FDA is requiring revisions to the Boxed Warning, FDA’s most prominent warning, for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious heart-related events, cancer, blood clots, and death.

    View detail
  6. regulatoryJun 15, 2026

    FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)

    Application ANDA218417. Sponsor: AUROBINDO PHARMA LTD. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: DEXTROMETHORPHAN POLISTIREX.

    View detail
  7. regulatoryJun 15, 2026

    Guidance: AI Airlock Sandbox Phase 2 Programme Report

    The MHRA’s AI Airlock second phase ran between April 2025 and May 2026. This report does not constitute formal MHRA guidance.

    View detail
  8. regulatoryJun 15, 2026

    FDA AP — AUVELITY (SUPPL)

    Application NDA215430. Sponsor: AXSOME. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: BUPROPION HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE.

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Strategic consideration for portfolio teams to evaluate COVAC-2's role in global vaccination efforts and its potential to fill gaps in booster vaccination strategies. The strongest clinical anchor is A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism (ClinicalTrials.gov), moderate corpus alignment. In Infectious Disease · COVID-19, 1 regulatory and 4 competitive items passed relevance filtering for COVAC-2. This becomes more urgent if Monitor further trial phases, regulatory approvals, and uptake in low- and middle-income countries. Additional medium- or high-relevance evidence would materially upgrade this assessment. Timeline shift beyond mid term would change urgency. A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)

    FDA

    Source: FDA

    View evidence

  • A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism

    ClinicalTrials.gov

    Source: ClinicalTrials.gov

    View evidence

  • Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects

    ClinicalTrials.gov

    Source: ClinicalTrials.gov

    View evidence

  • A Study to Learn About the Safety and Immune Response of New Pneumococcal Vaccine in Adults

    ClinicalTrials.gov

    Source: ClinicalTrials.gov

    View evidence

  • A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)

    ClinicalTrials.gov

    Source: ClinicalTrials.gov

    View evidence

  • Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

    ClinicalTrials.gov

    Source: ClinicalTrials.gov

    View evidence

  • Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

    ClinicalTrials.gov

    Source: ClinicalTrials.gov

    View evidence

  • Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Patients With Huntington's Disease (HD) Chorea in China

    ClinicalTrials.gov

    Source: ClinicalTrials.gov

    View evidence

  • New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)

    high relevance

    Discover potential signals of serious risks and new safety information identified by the FDA's Adverse Event Monitoring System (AEMS). Learn how the FDA monitors and evaluates drugs for safety concerns, providing important updates on adverse events to protect public health.

    Source: FDA

    View evidence

  • A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism

    medium relevance

    This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in primary aldosteronism.

    Source: ClinicalTrials.gov

    View evidence

  • Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects

    medium relevance

    The goal of this clinical trial is to learn if Test Product KSHB002 shows equivalence in terms of PK , safety and immunogenicity as compared to reference product ORENCIA used to treat Rheumatoid arthritis .

    Source: ClinicalTrials.gov

    View evidence

  • A Study to Learn About the Safety and Immune Response of New Pneumococcal Vaccine in Adults

    medium relevance

    The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults. This vaccine can possibly provide protection against further pneumococcal disease. This study will happen in 4 stages: Stage 1 is seeking participants who are between 18 years to 49 years of age. The participants will receive 1 of 2 pneumococcal vaccine candidates (different formulations) or 20vPnC (Prevnar 20) as a single shot given into the upper arm muscle.

    Source: ClinicalTrials.gov

    View evidence

  • A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)

    medium relevance

    This is Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of CU-20101 in the treatment of moderate to severe glabellar lines. The study consisted of a 7-day screening period, Study Part 1 (randomized double-blind controlled study) and Period 2 (open-label study).

    Source: ClinicalTrials.gov

    View evidence

  • Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

    medium relevance

    The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works to treat ALS. Participants will: Take pridopidine or a placebo by mouth every day for 48 weeks.

    Source: ClinicalTrials.gov

    View evidence

  • Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

    medium relevance

    The proposed study is an open-label, single arm phase II study of venetoclax in combination with rituximab in patients over the age of 60 with previously untreated mantle cell lymphoma. The primary objective of the trial is to determine whether the combination of venetoclax with rituximab in this patient population yields a clinically acceptable proportion of overall responses (ORR, assessed by PET/CT with Lugano criteria) without chemotherapy.

    Source: ClinicalTrials.gov

    View evidence

  • Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Patients With Huntington's Disease (HD) Chorea in China

    medium relevance

    The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult patients with chorea associated with Huntington's disease in China. The Secondary Objectives: To evaluate the real-world safety of deutetrabenazine in adult patients with chorea associated with Huntington's disease in China.

    Source: ClinicalTrials.gov

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • COVAC-2 Vaccine Shows Safety and Immunogenicity as COVID-19 Booster in Phase 1 Trial

    Trial Update

Insights

  • COVAC-2 Vaccine Emerges as Competitive Booster Option in Resource-Limited Settings

    Infectious Disease · COVID-19

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.